Abstract
Objectives This study aimed to estimate the 10-year cardiovascular diseases (CVD) risk in Bangladeshi adults using updated 2019 WHO laboratory-based and non-laboratory-based models, identify key CVD risk determinants, and assess the agreement between two models.
Methods We conducted a cross-sectional analysis of nationally representative Bangladesh STEPS 2018 survey data, involving 2767 adults aged 40-69 years without prior CVDs, using both versions of the updated 2019 WHO 10-year CVD risk prediction models. Logistic regression identified determinants and model agreement was assessed using Bland-Altman Plot, concordance, and Kappa statistics with STATA version 17.
Results In the laboratory-based model, 10.32% (95% CI: 8.78-12.11) of the population was at elevated risk (≥10%), while the non-laboratory-based model showed 9.25% (95% CI: 7.7-11.08). Males had significantly higher risk than females in both models (p<0.0001). Elevated 10-year CVD risk was associated with age increments of five years (OR=4.29, 95% CI: 3.48-5.30), being female (OR=0.31, 95% CI: 0.18-0.53), urban residence (OR=1.82, 95% CI: 1.20-2.74), residing in Dhaka division (OR=2.44, 95% CI: 1.26-4.73), and higher education (OR=2.42, 95% CI: 1.06-5.51). Key metabolic factors included high waist-hip ratio (OR=2.08, 95% CI: 1.22-3.52) and elevated triglycerides (OR=2.70, 95% CI: 1.65-4.41). Comparing models, Bland-Altman plots showed limit of agreement (-3.16, 3.52) with mean difference of 0.18, proportional bias (males: y=-0.43 + 1.11x; females: y=-0.43 + 1.16x), Lin’s Concordance Correlation Coefficient (LCCC) 0.90 (95% CI: 0.89-0.91), and a Kappa statistic of 0.69 (95%CI: 0.67-0.72).
Conclusion A substantial portion of the adult Bangladeshi population is at elevated risk of a cardiovascular event within the next decade, with males at higher risk per both models. Sociodemographic, and metabolic factors indicating potential target groups for intervention. The non-laboratory-based model generally shows agreement with the laboratory-based model and can serve as an alternative in settings with limited laboratory resources, though caution is advised for high-risk individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol for the 2018 Bangladesh STEPS study was approved by the Bangladesh Medical Research Council (BMRC). Before conducting interviews and collecting specimens, informed written consent was obtained from all participants. Furthermore, in March 2023, the NCD Microdata Repository of the World Health Organization (WHO) granted permission to access and use the dataset. Since this research involves secondary data that was collected with prior ethical approval and participant consent, no additional ethical clearance or further consent for publication was required. Our study complies with the ethical guidelines for the analysis of secondary data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: dr.monower{at}gmail.com, Email: Shehababid79{at}gmail.com, Email: mahfuzdoc{at}yahoo.com, Email: abdullah.mmcm26{at}gmail.com, Email: choudhurys{at}nhf.org.bd
